Definitive Contract 75N93019C00031
Award Date
8/1/19
Potential Completion Date
7/31/23
Potential Value
$1.5M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Zymeron Corporation
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Research Triangle Park, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
4
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,272,000.00 Firm Fixed Price, Definitive Contract to Zymeron Corporation, a minority-owned, for-profit biotechnology company. The contract is for the development of "Rapid Point of Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood" under the Small Business Innovation Research (SBIR) Program Phase II. This research aligns with the...
This is a $299,998.00 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Zymeron Corporation, a Minority Owned small business, under the Small Business Innovation Research (SBIR) program. The contract is for Phase I research and development related to "Combinatory Treatment Modalities Utilizing Radiation to Locally Activate or Release Systemically Delivered Therapeutics", as part of SBIR Topic...
This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Small Business Innovation Research (SBIR) Phase I contract to Zymeron Corporation, a minority-owned biotechnology company, to develop rapid point-of-care tests to simultaneously quantify anti-tuberculosis drugs in blood. The $299,920 contract, awarded on August 26, 2019, supports research and development to advance innovative diagnostics and...
This is a firm-fixed-price purchase order contract awarded by the U.S. Army Research, Development and Engineering Command (RDECOM) to Zymeron Corporation, a minority-owned, for-profit biotechnology company, under the Small Business Innovation Research (SBIR) Program Phase I. The contract, valued at $197,000.00, is for research and development services related to an unspecified biomedical or public health initiative. As a total small business set-aside, this award aligns with Zymeron's...
This is a $149,967.27 Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense to Zymeron Corporation, a minority-owned small business. The contract supports research and development of innovative biotechnology solutions related to areas such as protein degradation, antibacterials, antivirals, and drug delivery systems. As a prime contractor, Zymeron has a history of providing medical...
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a Small Business Innovation Research (SBIR) Phase I contract to Zymeron Corporation, a minority-owned biotechnology company, with a ceiling value of $300,000.00. The objective of this firm-fixed-price contract is for Zymeron to design and synthesize compounds that bind to Nef, an HIV accessory protein, as part of the agency's Small Molecule Degraders of Intracellular HIV Proteins as Novel Anti-HIV Therapeutics major...
The Zymeron Corporation was awarded a $299,998 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract is for the research and development of a rapid point-of-care diagnostic test for histoplasmosis. This award falls under the larger SBIR solicitation issued by NIH and CDC seeking proposals in areas including cancer immunotherapy manufacturing, opioid withdrawal...
This is a $299,988 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Zymeron Corporation, a minority-owned small business. The contract is for the development of novel, low-cost, real-time point-of-care (POC) assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring. This contract was awarded under the Small Business Innovation...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $300,000.00 firm-fixed-price definitive contract to Zymeron Corporation, a minority-owned small business, to provide rapid point-of-care tests to quantify hepatitis C virus. The contract has an estimated completion date of August 30, 2022 and was awarded on August 31, 2021. Zymeron is a research-based biotechnology company that develops innovative technologies...